Trial Profile
Randomised Comparisons, in Myeloma Patients of All Ages, of Thalidomide, Lenalidomide, Carfilzomib and Bortezomib Induction Combinations, and of Lenalidomide and Combination Lenalidomide Vorinostat as Maintenance (Myeloma XI)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Feb 2025
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Carfilzomib (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Melphalan (Primary) ; Thalidomide (Primary) ; Vorinostat (Primary) ; Stem cell therapies
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms Myeloma XI+; Myeloma-XI; UK NCRI Myeloma XI; Ukmrc Myeloma XI
Most Recent Events
- 12 Dec 2023 Results assessing The Impact of Epstein-Barr Virus Infection on Second Cancer Development in Newly Diagnosed Myeloma Patients Treated with Lenalidomide presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 13 Dec 2022 Results (n=4358)assessing the impact of len on SPM development when used at induction and maintenance, profiling SPM type and incidence, presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 13 Dec 2022 Results (from two studies OPTIMUM/MUKnine and Myeloma XI ) assessing outcomes for OPTIMUM patients until end of consolidation therapy and contextualise results with outcomes of UHiR MM patients treated in the Myeloma XI presented at the 64th American Society of Hematology Annual Meeting and Exposition.